05.04.2013 • NewsTevaLonzaCollaboration

Teva - Lonza Evaluates Biosimilars Opportunity

The Teva-Lonza Joint Venture issued the following statement today:

The potential to develop, manufacture and market affordable, efficacious and safe biosimilars remains an area of significant opportunity for both Teva and Lonza.

There is significant regulatory uncertainty in the biosimilars arena at present. Therefore, both companies are taking a measured approach, choosing to fully evaluate the prevailing regulatory and commercial circumstances before agreeing on further long-term investment decisions that both partners are comfortable with.

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.